Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Reserach programme: T cell receptor (TCR)-guided T Cell Engagers - EpimAb Biotherapeutics/Medigene

Next Previous
Search
Drug Profile

Reserach programme: T cell receptor (TCR)-guided T Cell Engagers - EpimAb Biotherapeutics/Medigene

Alternative Names: TCR-guided T cell engagers - EpimAb Biotherapeutics/Medigene; TCR-TCEs - EpimAb Biotherapeutics/Medigene

Latest Information Update: 28 Mar 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator EpimAb Biotherapeutics; MediGene AG
  • Class Antibodies; Antineoplastics; Immunoglobulin fragments; Immunotherapies; Recombinant fusion proteins
  • Mechanism of Action Cytotoxic T lymphocyte stimulants; Immunologic cytotoxicity
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Solid tumours

Most Recent Events

  • 27 Feb 2025 Medigene and EpimAb Biotherapeutics enter into a co-development partnership agreement to develop T cell receptor (TCR)-guided T Cell Engagers for Solid tumours
  • 27 Feb 2025 Early research in Solid tumours in China, Germany, China (Parenteral), prior to February 2025
  • 05 Dec 2024 Medigene has patent protection for 3S (sensitive, specific, and safe) TCRs and exclusive E2E Platform technologies in World

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top